IgA nephropathy does not almost always lead to dialysis, with current standard of care (RAAS blockade, SGLT2i, BP control), many patients never reach kidney failure
It is still too early to assess the promise of these cell therapy assets relative to semaglutide and tirzepatide
Contact us to learn how our platform can accelerate your program
By week 12, you should have completed the standard dose escalation protocol
Patients whose condition is driven predominantly by metabolic, microvascular, or inflammatory stress will derive greater benefit from cellular GPx1 mimetics than patients presenting with primary mechanical fluid obstructions or genetic structural anomalies
Or maybe youve been quietly researching on your phone at 2 a.m., wondering if these weight loss injections could finally be the thing that works for you